Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma

Brittany E. Givens, Sean M. Geary, Aliasger K. Salem

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.

Original languageEnglish
Pages (from-to)595-604
Number of pages10
Issue number7
StatePublished - Jun 2018

Bibliographical note

Publisher Copyright:
© 2018 Future Medicine Ltd.


  • CpG-ODN
  • Th1 cytokines
  • Th2 cytokines
  • allergic asthma
  • nanoparticles
  • prophylactic treatment
  • therapeutic treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma'. Together they form a unique fingerprint.

Cite this